Jenna May Kim1, Sarah Weiss2,3, John H Sinard1,4, Renelle Pointdujour-Lim1,2. 1. Department of Ophthalmology and Visual Science at Yale University School of Medicine, New Haven, Connecticut, USA. 2. Yale Smilow Cancer Center at Yale University School of Medicine, New Haven, Connecticut, USA. 3. Department of Internal Medicine at Yale University School of Medicine, New Haven, Connecticut, USA. 4. Department of Pathology, Yale New Haven Hospital, New Haven, Connecticut, USA.
Abstract
BACKGROUND: Conjunctival melanoma is a potentially lethal malignancy of the ocular surface. There have been no therapeutic advancements made in the past several decades despite increasing prevalence of the disease. METHODS: The authors report the case of a 52-year-old Caucasian male with unresectable, recurrent conjunctival melanoma with V600 BRAF mutation who was treated with systemic BRAF/MEK inhibition. RESULTS: There was complete regression of local disease within the first 9 months. The patient remains without local recurrence or systemic metastasis at 1 year. CONCLUSION: This is the first reported case of conjunctival melanoma with complete response to BRAF/MEK inhibition. As long as targeted therapy remains an option, patients with conjunctival melanoma should undergo mutational profiling of their tumor.
BACKGROUND: Conjunctival melanoma is a potentially lethal malignancy of the ocular surface. There have been no therapeutic advancements made in the past several decades despite increasing prevalence of the disease. METHODS: The authors report the case of a 52-year-old Caucasian male with unresectable, recurrent conjunctival melanoma with V600 BRAF mutation who was treated with systemic BRAF/MEK inhibition. RESULTS: There was complete regression of local disease within the first 9 months. The patient remains without local recurrence or systemic metastasis at 1 year. CONCLUSION: This is the first reported case of conjunctival melanoma with complete response to BRAF/MEK inhibition. As long as targeted therapy remains an option, patients with conjunctival melanoma should undergo mutational profiling of their tumor.
Authors: Carol L Shields; Jeremy S Markowitz; Irina Belinsky; Hal Schwartzstein; Nina S George; Sara E Lally; Arman Mashayekhi; Jerry A Shields Journal: Ophthalmology Date: 2010-08-17 Impact factor: 12.079
Authors: Lora R Dagi Glass; Donald P Lawrence; Frederick A Jakobiec; Suzanne K Freitag Journal: Ophthalmic Plast Reconstr Surg Date: 2017 Sep/Oct Impact factor: 1.746
Authors: Ann-Cathrine Larsen; Christina M Dahmcke; Christina Dahl; Volkert D Siersma; Peter B Toft; Sarah E Coupland; Jan U Prause; Per Guldberg; Steffen Heegaard Journal: JAMA Ophthalmol Date: 2015-11 Impact factor: 7.389
Authors: Guy S Missotten; Sander Keijser; Rob J W De Keizer; Didi De Wolff-Rouendaal Journal: Invest Ophthalmol Vis Sci Date: 2005-01 Impact factor: 4.799
Authors: Martine J Jager; Robert M Verdijk; Jinfeng Cao; Renier C Heijkants; Aart G Jochemsen; Mehmet Dogrusöz; Mark J de Lange; Pieter A van der Velden; Sjoerd H van der Burg Journal: Oncotarget Date: 2016-07-22
Authors: G V Long; K T Flaherty; D Stroyakovskiy; H Gogas; E Levchenko; F de Braud; J Larkin; C Garbe; T Jouary; A Hauschild; V Chiarion-Sileni; C Lebbe; M Mandalà; M Millward; A Arance; I Bondarenko; J B A G Haanen; J Hansson; J Utikal; V Ferraresi; P Mohr; V Probachai; D Schadendorf; P Nathan; C Robert; A Ribas; M A Davies; S R Lane; J J Legos; B Mookerjee; J-J Grob Journal: Ann Oncol Date: 2017-07-01 Impact factor: 32.976